HIV-1 逆转录酶中的 N348I 突变与其他耐药突变联合降低了对替诺福韦和依曲韦林的敏感性。
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
机构信息
University of Pittsburgh School of Medicine, Department of Medicine, Pittsburgh, PA, USA.
出版信息
AIDS. 2010 Jan 16;24(2):317-9. doi: 10.1097/QAD.0b013e3283315697.
Abstract
We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.
摘要
我们之前已经证明，HIV-1 逆转录酶中的 N348I 会导致齐多夫定和奈韦拉平耐药。然而，这两种抑制剂目前在发达国家已很少使用，且 N348I 对新型逆转录酶抑制剂（如替诺福韦和依法韦仑）的影响尚不清楚。在本研究中，我们证实，N348I 单独存在时不会赋予替诺福韦耐药性，仅对依法韦仑产生低水平耐药性。然而，当 N348I 与胸苷类似物突变联合时，会显著降低替诺福韦的敏感性，而当与 Y181C 联合时，则会降低依法韦仑的敏感性。
相似文献
1
N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
AIDS. 2010 Jan 16;24(2):317-9. doi: 10.1097/QAD.0b013e3283315697.
2
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
PLoS Med. 2007 Dec;4(12):e335. doi: 10.1371/journal.pmed.0040335.
3
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4.
4
N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
AIDS. 2010 Mar 13;24(5):659-67. doi: 10.1097/QAD.0b013e328336781d.
5
Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
Antivir Ther. 2010;15(2):203-11. doi: 10.3851/IMP1511.
6
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.
7
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.
Antimicrob Agents Chemother. 2012 May;56(5):2305-13. doi: 10.1128/AAC.05487-11. Epub 2012 Feb 13.
8
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
J Antimicrob Chemother. 2015 Feb;70(2):562-5. doi: 10.1093/jac/dku395. Epub 2014 Oct 25.
9
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
J Antimicrob Chemother. 2010 Jul;65(7):1477-85. doi: 10.1093/jac/dkq140. Epub 2010 May 12.
10
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
HIV Med. 2008 Aug;9(7):508-13. doi: 10.1111/j.1468-1293.2008.00581.x. Epub 2008 May 15.
引用本文的文献
1
Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.
Curr HIV Res. 2022;20(1):32-41. doi: 10.2174/1570162X19666210910144433.
2
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13.
3
A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity.
PLoS One. 2013 Oct 2;8(10):e74078. doi: 10.1371/journal.pone.0074078. eCollection 2013.
4
N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):153-7. doi: 10.1097/QAI.0b013e3182657990.
5
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Clin Infect Dis. 2012 Sep;55(5):737-45. doi: 10.1093/cid/cis501. Epub 2012 May 22.
6
Drug resistance in HIV-1.
Curr Opin Virol. 2011 Dec;1(6):582-9. doi: 10.1016/j.coviro.2011.10.020.
7
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine.
Antimicrob Agents Chemother. 2012 Feb;56(2):751-6. doi: 10.1128/AAC.05821-11. Epub 2011 Nov 28.
8
Advances in HIV microbicide development.
Future Med Chem. 2011 Dec;3(16):2101-16. doi: 10.4155/fmc.11.153.
9
Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1.
HIV AIDS (Auckl). 2010;2:141-9. doi: 10.2147/hiv.s5854. Epub 2010 Jun 28.
10
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
J Antimicrob Chemother. 2011 Apr;66(4):702-8. doi: 10.1093/jac/dkr005. Epub 2011 Jan 26.
本文引用的文献
1
2
Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.
Antiviral Res. 2009 Jun;82(3):115-21. doi: 10.1016/j.antiviral.2009.02.189. Epub 2009 Feb 21.
3
Update of the Drug Resistance Mutations in HIV-1.
Top HIV Med. 2008 Dec;16(5):138-45.
4
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA. 2008 Aug 6;300(5):555-70. doi: 10.1001/jama.300.5.555.
5
Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
Trop Med Int Health. 2008 Jul;13(7):870-9. doi: 10.1111/j.1365-3156.2008.02078.x. Epub 2008 Mar 27.
6
Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients.
PLoS One. 2008 Mar 12;3(3):e1781. doi: 10.1371/journal.pone.0001781.
7
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
J Virol. 2008 Apr;82(7):3261-70. doi: 10.1128/JVI.01154-07. Epub 2008 Jan 23.
8
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
PLoS Med. 2007 Dec;4(12):e335. doi: 10.1371/journal.pmed.0040335.
9
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2007 Jul 7;370(9581):39-48. doi: 10.1016/S0140-6736(07)61048-4.
10
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lancet. 2007 Jul 7;370(9581):29-38. doi: 10.1016/S0140-6736(07)61047-2.
Zotero 插件